

June 18, 2007

Astellas Announces the Launch of Advagraf[®] in the UK and Germany

Tokyo Japan, June 18, 2007 - Astellas Pharma Inc. (headquarters: Tokyo, President and CEO: Masafumi Nogimori, “Astellas”) today announced the launch of the immunosuppressant, Advagraf (generic name: tacrolimus, prolonged release capsules) in the UK and Germany by Astellas’ European subsidiaries on June 18, 2007 (local time).

Astellas’ European subsidiary submitted a Marketing Authorization Application (MAA) for Advagraf under the centralised procedure to the European Medicines Agency (EMA) in January 2006. This was followed by the European Commission’s approval of Advagraf on April 23, 2007. Advagraf is indicated for the “Prophylaxis of transplant rejection in adult kidney or liver allograft recipients, treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.”

The availability of Advagraf in the UK and Germany represents the first of a Europe-wide launch, with additional country launches to follow.

Advagraf is a once-daily formulation of Prograf[®] (tacrolimus, twice-daily formulation), the leading immunosuppressive agent developed by Astellas. Advagraf is expected to improve long-term compliance with its more convenient once-daily dosing option, and may have the potential to reduce the incidence of graft loss.

Prograf is marketed in over 70 countries around the world for the prevention of organ rejection in transplantation. As a leading company in the transplantation community throughout Europe, Astellas aims to further advance the care and management of people with organ transplants with the new lineup for Prograf family.

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com